Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Genomic Research Center, |
RCV000502221 | SCV000590930 | likely pathogenic | Peroxisome biogenesis disorder 3A (Zellweger) | 2020-05-03 | criteria provided, single submitter | clinical testing | |
Counsyl | RCV000670939 | SCV000795861 | likely pathogenic | Peroxisome biogenesis disorder type 3B; Peroxisome biogenesis disorder 3A (Zellweger) | 2017-11-21 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV003403180 | SCV004122725 | pathogenic | Peroxisome biogenesis disorder | 2023-10-11 | criteria provided, single submitter | clinical testing | Variant summary: PEX12 c.533_535delAAC (p.Gln178del) results in an in-frame deletion that is predicted to remove 1 amino acids from the encoded protein. The variant allele was found at a frequency of 1.6e-05 in 251488 control chromosomes. c.533_535delAAC has been reported in the literature in multiple individuals affected with Zellweger Syndrome (Alshenaifi_2019, Yik_2009, Steinberg_2004, Ebberink_2010). These data indicate that the variant is very likely to be associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. The following publications have been ascertained in the context of this evaluation (PMID: 30561787, 21031596, 15542397, 19105186). Two submitters have cited clinical-significance assessments for this variant to ClinVar after 2014. All submitters classified the variant as likely pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. |
Baylor Genetics | RCV000502221 | SCV004201452 | likely pathogenic | Peroxisome biogenesis disorder 3A (Zellweger) | 2024-03-29 | criteria provided, single submitter | clinical testing |